Strategic use of new generation antidepressants for depression: SUN(^_^) D protocol update and statistical analysis

Naohiro Yonemoto1,2, Shiro Tanaka3, Toshi A Furukawa4,5

  • 1Department of Neuropsychopharmacology, National Institute of Mental Health, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo, 187-8553, Japan. nyonemoto@gmail.com.

Trials
|October 16, 2015
PubMed
Abstract

Insights

The SUN(^_^)D trial updates its protocol for major depressive episodes, optimizing first- and second-line antidepressant strategies. This pragmatic mega-trial ensures unbiased reporting of treatment effectiveness.

Area of Science:

  • Psychiatry and Clinical Psychology
  • Pharmacology and Pharmaceutical Sciences

Background:

  • The SUN(^_^)D trial investigates optimal treatment strategies for unipolar major depressive episodes.
  • It employs a pragmatic mega-trial design with three steps and two randomizations for first- and second-line antidepressant treatments.
  • The trial was registered on ClinicalTrials.gov (NCT01109693) in April 2010.

Purpose of the Study:

  • To present the updated protocol and statistical analysis plan for the SUN(^_^)D trial.
  • To refine the reporting of primary and secondary outcomes for enhanced clinical relevance.
  • To minimize reporting bias and data-driven results in the trial analysis.

Main Methods:

  • An assessor-blinded, parallel-group, multicenter pragmatic mega-trial design.
  • Step I: Minimum vs. maximum dosing for first-line antidepressants.
  • Step II: Continuation, augmentation, or switching strategies for second-line antidepressants; Step III: Naturalistic continuation phase.

Main Results:

  • Two key protocol changes were implemented: sample size adjustment due to lower dropout rates and refined outcome organization.
  • The updated protocol details primary and secondary outcomes and their analyses for two separate main results reports.
  • A blind interpretation committee will convene before randomization codes are broken.

Conclusions:

  • This updated protocol and statistical analysis plan facilitate unbiased and interpretable reporting of the SUN(^_^)D trial findings.
  • The modifications aim to enhance the clinical applicability of the results regarding antidepressant treatment strategies.
  • The trial is structured to provide robust evidence on optimizing depression management.

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
2.0K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
2.1K
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
1.2K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
922
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
467